Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain.

ABSTRACT:

Background

Cancer is a global public health problem, requiring efficient health system investments to deliver sustainable impact on population health. Access to medicines is a critical component of health systems, having a crucial role in delivering therapeutic benefits. Since 1977, the World Health Organization (WHO) has published a Model List of Essential Medicines (EML) that includes key health interventions for the prevention and control of conditions of public health relevance. Essential medicines are selected for inclusion in the EML based on the evidence of efficacy, safety, therapeutic value, and the potential to impact population health. With the rapid changes in the therapeutic landscape of cancer treatment with new medicine approvals, there is a critical need to select a

SUBMITTER: Roitberg F 

PROVIDER: S-EPMC10594014 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature